The stock market got its Halloween scare a bit early this year.

On Oct. 30, Intel told investors the rest of the year would be weaker than they’d hoped, and by the closing bell, its shares had tanked nearly 30%.

Amazon slid after its own disappointing report, and Dell followed it down.

But the selling didn’t stop with the companies that delivered bad news.

For weeks, investors had been quietly wondering whether the hundreds of billions of dollars pouring into AI would ever pay for themselves.

That day, a lot of them decided they’d rather not wait around for the answer, so they sold almost anything whose value rested on a big promise about tomorrow.

Yet another corner of the market seemed to be having a completely different week…

Big Pharma Handed Out the Treats

Eli Lilly gave investors an early treat on Oct. 29, climbing more than 6% to a record close while the broader market slipped.

The next day, as Intel was having one of the worst days in its history, AstraZeneca jumped about 7%.

So right before trick-or-treat, with the whole market on edge, two of the world’s biggest drugmakers were heading the other way.

What did they have that Intel didn’t?

Both beat Wall Street’s expectations for the quarter, but Lilly went a step further.

It told investors it now expects to bring in about $5.5 billion more this year than it forecast just a few months ago, which is more than plenty of well-known public companies make in an entire year.

Almost all of that comes from two drugs people are lining up for right now: Mounjaro and Zepbound.

Nobody Skips Their Medicine Over a Bad Report

When you buy into the AI boom, you’re buying a vision.

It may pay off enormously, but much of the money being spent today won’t show up as profit for years, and nobody knows exactly how much of it ever will.

When markets are calm, investors are happy to wait for that payoff, but once nerves kick in, waiting suddenly feels a lot riskier.

A weight-loss drug doesn’t ask anyone to wait.

Patients are filling prescriptions this month, doctors are writing more of them next month, and the revenue is already landing.

People don’t skip their medication because a chipmaker had a bad quarter or the market had a rough week.

That kind of steadiness rarely makes headlines when everything’s rising, but when the market turns jittery, it’s exactly where a lot of investors want their money.

What Drug Giants Do With All That Cash

Companies like Lilly and AstraZeneca can’t afford to sit on their profits, because every blockbuster drug eventually loses its patent protection.

When that happens, cheaper copies flood in, and billions in yearly sales can start disappearing almost overnight.

So the big drugmakers are always hunting for whatever comes next, and more and more often, they find it by buying it.

They let smaller biotech companies take on the early, risky work of discovering and testing new treatments, then write a very large check once the science starts to look promising.

Merck paid about $10 billion for Verona Pharma after its lung treatment reached the market, and Pfizer paid roughly $14 billion for Medivation and its prostate cancer franchise.

Now imagine what happens when those same buyers are raising their forecasts and watching their share prices climb — they get even more firepower to go shopping.

That doesn’t mean every small biotech is about to be bought out, since most experimental drugs never make it to market.

But when the industry’s biggest buyers are flush with cash, the companies with something worth buying tend to get a lot more attention.

Before You Pile Into Pharma

None of this means tech is finished or that drug stocks only go up.

One strong quarter doesn’t guarantee another, and Lilly’s shares were already expensive heading into the week.

A company that leans this heavily on a couple of products carries its own kind of risk, especially with competitors racing to launch weight-loss drugs of their own and pricing pressure from Washington still hanging over the industry.

And if the next round of tech earnings calms fears about AI spending, some of that money could flow right back where it came from.

Still, that week was a useful reminder. When markets get jumpy, investors stop asking how big a company could become and start asking what it’s earning today.

The next few weeks should show whether that week’s move was a one-off flinch or the start of something bigger.

Either way, it’s worth watching where the money goes when the market gets scared.